Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib vs paclitaxel/irinotecan as second-line therapy for gastric cancer
CTR20200045Phase 3Suspended
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Hengrui Therapeutics. Started Jan 2020; status: suspended.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20200045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200045.